DK1497330T3 - Antagonister af faktor-VIII-interaktion med lav-densitets- lipoproteinreceptor-relateret protein - Google Patents
Antagonister af faktor-VIII-interaktion med lav-densitets- lipoproteinreceptor-relateret proteinInfo
- Publication number
- DK1497330T3 DK1497330T3 DK03725109.7T DK03725109T DK1497330T3 DK 1497330 T3 DK1497330 T3 DK 1497330T3 DK 03725109 T DK03725109 T DK 03725109T DK 1497330 T3 DK1497330 T3 DK 1497330T3
- Authority
- DK
- Denmark
- Prior art keywords
- factor viii
- interaction
- antagonists
- low
- lrp
- Prior art date
Links
- 102000001690 Factor VIII Human genes 0.000 title abstract 9
- 108010054218 Factor VIII Proteins 0.000 title abstract 9
- 229960000301 factor viii Drugs 0.000 title abstract 9
- 230000003993 interaction Effects 0.000 title abstract 4
- 101710172064 Low-density lipoprotein receptor-related protein Proteins 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 102100021923 Prolow-density lipoprotein receptor-related protein 1 Human genes 0.000 abstract 3
- 239000013060 biological fluid Substances 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 201000003542 Factor VIII deficiency Diseases 0.000 abstract 2
- 208000015294 blood coagulation disease Diseases 0.000 abstract 2
- 230000015556 catabolic process Effects 0.000 abstract 2
- 238000006731 degradation reaction Methods 0.000 abstract 2
- 230000005764 inhibitory process Effects 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Surgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37635102P | 2002-04-29 | 2002-04-29 | |
| PCT/EP2003/004425 WO2003093313A2 (en) | 2002-04-29 | 2003-04-28 | Antagonists of factor viii interaction with low-density lipoprotein receptor-related protein |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1497330T3 true DK1497330T3 (da) | 2010-06-14 |
Family
ID=29401334
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK03725109.7T DK1497330T3 (da) | 2002-04-29 | 2003-04-28 | Antagonister af faktor-VIII-interaktion med lav-densitets- lipoproteinreceptor-relateret protein |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US8586538B2 (da) |
| EP (1) | EP1497330B1 (da) |
| JP (2) | JP2005535588A (da) |
| AT (1) | ATE463514T1 (da) |
| AU (1) | AU2003227687B2 (da) |
| CA (1) | CA2484155C (da) |
| DE (1) | DE60332011D1 (da) |
| DK (1) | DK1497330T3 (da) |
| ES (1) | ES2343681T3 (da) |
| WO (1) | WO2003093313A2 (da) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1539235A2 (en) | 2002-07-01 | 2005-06-15 | Human Genome Sciences, Inc. | Antibodies that specifically bind to reg iv |
| EP1454632A1 (en) * | 2003-02-07 | 2004-09-08 | Aventis Behring GmbH, Intellectual Property/Legal | Pharmaceutical preparation for the treatment of blood-clotting disorders containing factor VIII derived peptides |
| AR045563A1 (es) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
| WO2006003183A1 (de) * | 2004-07-02 | 2006-01-12 | Alois Jungbauer | Peptide zur blockierung von fviii-inhibitoren |
| EP1816201A1 (en) | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modified coagulation factor VIIa with extended half-life |
| JP2009274958A (ja) | 2006-08-31 | 2009-11-26 | Nara Prefecture | 血液凝固第ｖｉｉｉ因子の活性化を促進する抗体 |
| WO2008077616A1 (en) | 2006-12-22 | 2008-07-03 | Csl Behring Gmbh | Modified coagulation factors with prolonged in vivo half-life |
| CA2726942A1 (en) * | 2008-06-04 | 2009-12-10 | Bayer Healthcare Llc | Fviii muteins for treatment of von willebrand disease |
| KR101507718B1 (ko) | 2008-06-24 | 2015-04-10 | 체에스엘 베링 게엠베하 | 연장된 생체내 반감기를 갖는 인자 ｖｉｉｉ, 폰 빌레브란트 인자 또는 이들의 복합체 |
| JP5394864B2 (ja) * | 2009-09-10 | 2014-01-22 | アスモ株式会社 | モータ |
| WO2011095604A1 (en) * | 2010-02-04 | 2011-08-11 | Octapharma Biopharmaceuticals Gmbh | Half-life prolongation of proteins |
| EP2616486B1 (en) | 2010-09-15 | 2019-01-02 | Stichting Sanquin Bloedvoorziening | Factor viii variants having a decreased cellular uptake |
| PL2814502T3 (pl) | 2012-02-15 | 2018-02-28 | Csl Behring Gmbh | Warianty czynnika von Willebranda mające ulepszone powinowactwo do wiązania czynnika VIII |
| EP2796145B1 (en) | 2013-04-22 | 2017-11-01 | CSL Ltd. | A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge |
| BR112016030950A2 (pt) | 2014-07-02 | 2018-03-27 | Csl Ltd | polipeptídeo modificado que se liga ao fator viii, complexo, composição farmacêutica, métodos para tratar uma coagulopatia, para produzir um polipeptídeo que compreende um vwf modificado e para aumentar a afinidade de ligação ao fator viii do vwf e a meia-vida do fator viii, uso de um polipeptídeo modificado ou de um complexo, polinucleotídeo, plasmídeo ou vetor, e, célula hospedeira. |
| CN107406493B (zh) | 2015-03-06 | 2021-08-13 | 康诺贝林伦瑙有限公司 | 具有改善的半衰期的经修饰的血管性血友病因子 |
| CA2986625A1 (en) | 2015-05-22 | 2016-12-01 | Csl Behring Recombinant Facility Ag | Methods for preparing modified von willebrand factor |
| AU2016266627A1 (en) | 2015-05-22 | 2018-01-18 | CSL Behring Lengnau AG | Truncated von Willebrand Factor polypeptides for treating hemophilia |
| CN108779165B (zh) | 2016-01-07 | 2022-12-02 | 康诺贝林伦瑙有限公司 | 突变的冯·维勒布兰德因子 |
| RU2018128582A (ru) | 2016-01-07 | 2020-02-11 | Цсл Беринг Ленгнау Аг | Мутированный укороченный фактор фон виллебранда |
| DK3538133T3 (da) | 2016-11-11 | 2021-04-19 | CSL Behring Lengnau AG | Trunkeret von willebrand faktor polypeptider til behandling af hæmofili |
| EP3538134B1 (en) | 2016-11-11 | 2021-12-29 | CSL Behring Lengnau AG | Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU713303B2 (en) * | 1995-06-12 | 1999-11-25 | Stichting Centraal Laboratorium Van De Bloedtransfusiedienst Van Het Nederlandse Rode Kruis | Factor IX binding peptides, derived from factor VIII and their use as inhibitors of blood coagulation |
| EP1095143B1 (en) * | 1998-05-08 | 2008-08-20 | Stichting Sanquin Bloedvoorziening | Inhibitor for diagnosis and treatment of haemophilia a patients |
| AT409335B (de) * | 1998-11-10 | 2002-07-25 | Immuno Ag | Pharmazeutisches präparat enthaltend einen rezeptor-antagonisten zur behandlung von blutgerinnungsstörungen |
| DK1129186T4 (da) * | 1998-11-10 | 2017-02-06 | Stichting Sanquin Bloedvoorziening | Et faktor VIII-polypeptid med faktor VIII:C-aktivitet |
-
2003
- 2003-04-28 ES ES03725109T patent/ES2343681T3/es not_active Expired - Lifetime
- 2003-04-28 CA CA2484155A patent/CA2484155C/en not_active Expired - Lifetime
- 2003-04-28 DE DE60332011T patent/DE60332011D1/de not_active Expired - Lifetime
- 2003-04-28 US US10/512,907 patent/US8586538B2/en active Active
- 2003-04-28 EP EP03725109A patent/EP1497330B1/en not_active Expired - Lifetime
- 2003-04-28 JP JP2004501452A patent/JP2005535588A/ja active Pending
- 2003-04-28 WO PCT/EP2003/004425 patent/WO2003093313A2/en active Application Filing
- 2003-04-28 DK DK03725109.7T patent/DK1497330T3/da active
- 2003-04-28 AT AT03725109T patent/ATE463514T1/de active
- 2003-04-28 AU AU2003227687A patent/AU2003227687B2/en not_active Ceased
-
2010
- 2010-06-07 JP JP2010130425A patent/JP2010202664A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA2484155C (en) | 2015-10-13 |
| ES2343681T3 (es) | 2010-08-06 |
| AU2003227687A1 (en) | 2003-11-17 |
| WO2003093313A3 (en) | 2004-07-29 |
| JP2010202664A (ja) | 2010-09-16 |
| EP1497330B1 (en) | 2010-04-07 |
| DE60332011D1 (de) | 2010-05-20 |
| EP1497330A2 (en) | 2005-01-19 |
| US8586538B2 (en) | 2013-11-19 |
| CA2484155A1 (en) | 2003-11-13 |
| AU2003227687B2 (en) | 2009-10-15 |
| US20080219983A1 (en) | 2008-09-11 |
| WO2003093313A2 (en) | 2003-11-13 |
| ATE463514T1 (de) | 2010-04-15 |
| JP2005535588A (ja) | 2005-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1497330T3 (da) | Antagonister af faktor-VIII-interaktion med lav-densitets- lipoproteinreceptor-relateret protein | |
| CY1110894T1 (el) | Μεθοδοι για θεραπεια ή προληψη αγγειακης φλεγμονης χρησιμοποιωντας αναστολεα (-εις) απορροφησης στερολης | |
| DE602004014117D1 (de) | Thiazole zur verwendung als inhibitoren von protein-kinasen | |
| CY1106879T1 (el) | Χρηση των αναστολεων αναγωγασης συνενζυμου α 3-υδροξυ-3-μεθυλογλουταρυλ για την παρασκευη ενος φαρμακου για την αντιμετωπιση της διαβητικης νευροπαθειας | |
| EA200500782A1 (ru) | Лечение геморрагического шока | |
| DK1970059T3 (da) | Lægemiddel med calciumdobesilat til behandling og profylakse af senelidelser | |
| ATE433973T1 (de) | Azolylaminoazine als inhibitoren von proteinkinasen | |
| ATE349446T1 (de) | Amyloid plaque aggregationshemmer und diagnostische bilderzeugungsmittel | |
| EA200500218A1 (ru) | ЛЕЧЕНИЕ ПОЧЕЧНОЙ НЕДОСТАТОЧНОСТИ С ПРИМЕНЕНИЕМ ИНТЕРФЕРОНА-β | |
| EA201100072A1 (ru) | Новые композиции и способы | |
| CY1112055T1 (el) | Συνθεσεις και μεθοδοι για την διαγνωση και θεραπευτικη αγωγη ογκου πνευμονα | |
| DE602005020611D1 (de) | Als inhibitoren von rock und anderen proteinkinasen geeignete zusammensetzungen | |
| EA200971053A1 (ru) | Способы лечения кожных язв | |
| BRPI0309665B8 (pt) | método para analisar uma preparação de alfagalactosidase a | |
| DE602004031134D1 (de) | Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa | |
| CY1107383T1 (el) | Αναστολεις της φωσφολιπασης α2 του κυτοπλασμικου διαλυματος | |
| DK1505990T3 (da) | Fremgangsmåder til behandling af hepatitis | |
| ATE314062T1 (de) | Zusammensetzungen zur abgabe von cortisolantagonisten | |
| EA201000630A1 (ru) | Применение бензоконденсированных гетероциклических сульфамидных производных для понижения уровней липидов в крови | |
| WO2004075838A3 (en) | Method and compositions for the treatment of meconium aspiration syndrome | |
| CY1109537T1 (el) | Πεπτιδια και παραγωγα πεπτιδιου, παρασκευη αυτων καθως επισης χρηση αυτων για την παρασκευη θεραπευτικως η/και προληπτικως δραστικης φαρμακευτικης συνθεσης | |
| AU2009246603A8 (en) | Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction | |
| WO2009049234A3 (en) | Methods of treating coagulopathy | |
| NO20073104L (no) | Anvendelse av en 5-HT6 agonist for behandling og forebygging av neurodegenerative forstyrrelser | |
| DE60319135D1 (de) | Peptide, die die heparinbindungsdomäne von vegf und vegfr-2 binden |